Search

everythinglearnresearchcommunity

for

Search:↓

Topical Vitamin D3 may stimulate hair growth and has been used for Alopecia Areata. There is a question about the lack of research on its use for Androgenetic Alopecia (AGA).

A user reported a significant increase in testosterone and estradiol levels after taking Finasteride for 5 months, with estradiol levels rising over 2000%. They plan to consult their doctor, suspecting a lab error, as they feel fine with no side effects.

Pyrilutamide shows promising hair growth results, but skepticism exists due to potential biases and lack of blinding in the study. Concerns about side effects and legitimacy of the product persist, with comparisons to finasteride and discussions on post-finasteride syndrome.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.

Considering alternative treatments to hair loss, such as platelet-rich plasma (PRP) and exosome therapy, instead of using medications like minoxidil, finasteride/dutasteride.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

A 20-year-old with thinning hair has low vitamin D and normal testosterone. They are prescribed oral minoxidil and vitamin D, and are questioning if finasteride is also necessary.

A 23-year-old male is considering starting Finasteride for hair loss after experiencing persistent shedding and hairline recession, with bloodwork showing normal testosterone levels but low DHEA-S and Vitamin D. He plans to discuss DHEA supplementation with his doctor and has already started Vitamin D supplementation.

The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

The conversation discusses skepticism over the results of Pyrilutamide for hair regrowth, suggesting that results from rigorous trials are more trustworthy. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A 25-year-old male experiencing diffuse thinning is advised to address high TSH levels and low iron, and consider treatments like finasteride. Weight loss and improved diet are also suggested to potentially help with hair health.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

The VT Reedle Shot, a skincare product using silica spicules, is discussed as a potential at-home alternative to microneedling for hair regrowth. It is suggested that different intensities may aid in hairline regrowth.

RU58841 helped reduce scalp itching for some users within a week, while others experienced immediate relief. Some users reported initial irritation from the solution, possibly due to the carrier used.

The user switched from finasteride to dutasteride due to side effects and is experiencing fewer side effects with dutasteride, though some scalp itching has occurred. Blood tests show elevated testosterone and estrogen, low DHT, and normal liver and cholesterol levels, leading the user to feel confident in the long-term benefits of dutasteride for hair regrowth.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

Treatment options for female alopecia androgenetica, discussing the availability of spironolactone online in The Netherlands and other potential treatments like finasteride, minoxidil and RU58841.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

The conversation confirms that to make a 5% RU58841 solution, 1.5 grams should be added to 30 mL of KB Solution. The discussion involves calculating the correct dosage for hair loss treatment.

Hair loss treatments including Minoxidil, Finasteride and RU58841; with a focus on Pyrilutamide could potentially be used as an effective treatment.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.